Biocon Biologics wins $90 mn contract from Malaysia to supply human insulin

Biocon Biologics, a subsidiary of Biocon on Tuesday said it has won a three-year contract valued at $90 million from Malaysian government to supply, its recombinant human insulin Insugen.

Biocon Sdn. Bhd. a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg), a subsidiary of Duopharma Biotech, a leading pharmaceutical & biotech company in Malaysia.

Biocon has a insulins manufacturing facility is Malaysia at Johor which has been approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia.


Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics, the company said.